Business
Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth
Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth.
About this update from Zomedica Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth\r\n \r\n \r\n\r\n\r\nZomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth\r\n\r\n\r\n\r\n\r\n\r\nZomedica posts record year-over-year revenue for 18th straight quarter! ANN ARBOR, MI / ACCESS Newswire / August 6, 2025 / Zomedica Corp. (OTCQB:ZOMDF) (\"Zomedica\" or the \"Company\"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2025.\r\n \"We are very pleased with the 14% growth attained in the second quarter as we posted record year-over-year revenue for the 18th straight quarter,\" said Larry Heaton, Chief Executive Officer of Zomedica. \"Bolstered by continued and robust usage of our therapeutic products, including our PulseVet® and Assisi® products, and the continued growth and adoption of our diagnostic products, including our expanding TRUFORMA® platform, we were able to deliver the strongest second quarter in company history.\r\n \"Through further expansion of our portfolio and the continued optimization of our commercial organization, we are seeing the positive impact in both placements and consumable usage as evidenced by 86% growth in our Diagnostic segment and 21% growth in total Consumable sales year-over-year. We believe this growth and the model in which these sales are generated further supports a foundation for recurring sales revenue in the future.\r\n \"International sales continue to grow, with sales up 13% compared to the second quarter of 2024, driven by a combination of organic growth and orders from new distributor partners.\r\n \"We are particularly pleased with the success of recent initiatives aimed at expanding our coverage and extending the use of our suite of products. During the quarter, we launched a national Equine Asthma registry which provides us with a low cost way to accumulate data to support expanded usage of our PulseVet system.\r\n \"To further strengthen the impact and reach of our products, we continue to work to identify gaps in market offer...